Experiment section domain ebi.ac.uk accession E-TABM-66 quality_control experiment_design_type cell_type_comparison_design name Comparison of normal and malignant human breast epithelial cells description "Multiple genome-wide microarrays have been used to analyse the transcriptomes of immunomagnetically separated normal human luminal epithelial and myoepithelial cells, as well as primary malignant breast epithelial cells." release_date submission_date submitter Anita Grigoriadis organization publication_title authors journal volume issue pages year Protocol section accession text name type parameters P-MEXP-10843 "100 ug total RNA of 352,453,463,621,688,697,723,729,794,1098 were combined." Myoepithelial pool pool P-MEXP-10844 "100 ug total RNA of 723,729,697,822,1016,1031,1040,1053,1123,1130 were combined." Luminal_epithelial_pool pool P-MEXP-10845 "50ug total RNA of 489,552,593,695,725,842,845,896,983,1000,1033,1045,1052,1062,1063 were combined" F19_breast_tumour_pool pool P-TABM-AnitaG-10115 "1. One round of amplification through to dye coupling reaction performed according to Amino Allyl MessageAmp aRNA Kit protocol (Ambion, cat #1752 http://www.ambion.com/techlib/prot/fm_1752.pdf ). Cy3 monoreactive dye (Amersham, cat# PA23001) or Cy5 (Amersham, cat# PA25001) used to label samples.
2. Rneasy Minelute Cleanup Kit (QIAGEN, cat #74204 http://www1.qiagen.com/literature/handbooks/PDF/RNACleanupAndConcentration/RNY_MinElute_Cleanup/1023760_HBRNYME0303WW.pdf ) protocol used to clean up labelled probe." aRNA labelling (Cy3/Cy5) labeling P-MEXP-14985 "For detail see CodeLink Gene Expression System:Manual Labelled cRNA Target Preparation:

Assessment of total RNA

1.1 See Appendix 2 and 3 to assess the quantity and quality of total RNA starting material prior to use in .rst-strand cDNA synthesis reaction.

Synthesis of first-strand cDNA

2.1 Prepare a working solution of bacterial control mRNAs (Appendix 4).

2.2 Prepare each total RNA sample for manual target preparation: 0.2 .2 ug total RNA

X ul working solution of bacterial control mRNAs

(1 ul per 1 ug input total RNA,dilute as required)

1 ul T7 oligo(dT)primer

Y ul nuclease-free water

12 ul .final volume

2.3 Incubate 10 minutes in a 70 oC water bath or incubator; immediately place the tube on ice until cool (3 minutes).

2.4 Centrifuge for 5 seconds to collect the sample at the bottom of the tube; return the tube to ice.

2.5 Keep the tube on ice and add the following reagents to the 12 ul of total RNA/control mRNA/primer mix from above.

2 ul 10 ?~first-strand buffer

4 ul 5 mM dNTP mix

1 ul RNase inhibitor

1 ul reverse transcriptase

20 ul final volume

2.6 Incubate 2 hours in a 42 oC water bath or air incubator.

2.7 Centrifuge for 5 seconds to collect the sample at the bottom of the tube.

Synthesis of second-strand cDNA

3.1 Prepare the following second-strand cDNA synthesis reaction mix for each sample from step 2:

20 ul first-strand cDNA reaction from step 2.7

63 ul nuclease-free water

10 ul 10 ?~second-strand buffer

4 ul 5 mM dNTP mix

2 ul DNA polymerase mix

1 ul RNase H

100 ul final volume

3.2 Gently tap the side of the tube to mix;then centrifuge for 5 seconds at 10 000 ?~g to combine the reactants. Incubate for 2 hours at 16 oC in an incubator.

3.3 Centrifuge for 5 seconds at maximum speed to collect the sample at the bottom of the tube. Mix gently and place the tube on ice. Proceed directly to step 4 or store the sample at -20 oC.

Purification of double-stranded cDNA

4.1 Add 500 ul buffer PB to the cDNA from step 3.3 and mix by gently pipetting up and down.

4.2 Place a QIAquick spin column into a 2-ml collection tube.

4.3 Transfer the cDNA buffer PB solution to the QIAquick spin column.

4.4 Centrifuge the spin column at 10 000 ?~g for 30 .60 seconds.

4.5 Discard the flow-through. To wash the column, add 700 ul buffer PE to the column and centrifuge at 10 000 ?~g for 30 seconds.

4.6 Discard the flow-through.To dry the column, place the QIAquick column into a new 2-ml collection tube and centrifuge at 10 000 ?~g for 1 minutes.

4.7 Place the QIAquick column into a clean 1.5-ml microcentrifuge tube.

4.8 To elute the cDNA, add 30 ul of EB buffer to the center of the QIAquick membrane. Let the column stand at ambient temperature for 1 minute, then centrifuge for 1 minute at 10 000 ?~g. Repeat once to generate a total of 60 ul eluate.

4.9 Concentrate the cDNA solution in a SpeedVac concentrator under medium heat to 9.5 ul final volume per tube. Do not dry cDNA to completion (pellet form)since the pellet is difficult to subsequently resuspend.

4.10 Measure and ensure that the cDNA is in a final volume of 9.5 ul nuclease-free water and vortex to mix well.

Synthesis of cRNA by in vitro transcription (IVT)

5.1 Make the IVT mixture by adding the following components,in the order listed,to another RNase-free microcentrifuge tube:

4.0 ul 10 ?~T7 Reaction Buffer

4.0 ul T7 ATP solution

4.0 ul T7 GTP solution

4.0 ul T7 CTP solution

3.0 ul T7 UTP solution

7.5 ul 10 mM biotin-11-UTP

4.0 ul 10 ?~T7 enzyme mix

30.5 ul final volume

5.2 Mix the components of the IVT mixture by briefly vortexing the tube. Centrifuge the tube for 5 seconds at 10 000 ?~g. Transfer this reaction mixture (30.5 ul)into the tube from step 4.10,and gently pipette up and down to ensure complete mixing.

5.3 Incubate the reaction for 14 hours in an air incubator at 37 oC.

Recovery of biotin-labelled cRNA

6.1 Prepare working solutions of the RLT and RPE buffers (Appendix 1).

6.2 Briefly centrifuge the IVT reaction tube to collect all contents at the bottom of the tube. Adjust the solution volume to 100 ul by adding 60 ul of nuclease-free water.

6.3 Add 350 ul buffer RLT to the sample and mix thoroughly by pipetting up and down.

6.4 Add 250 ul of 100%ethanol to the reaction sample and mix well by pipetting up and down. Do not centrifuge.

6.5 Apply the sample (700 ul) to an RNeasy spin column in a collection tube.

Centrifuge for 15 seconds at 8000 ?~g.

6.6 Transfer the RNeasy column into a new 2-ml collection tube (supplied).Add 500 ul of buffer RPE to column and centrifuge for 15 seconds at 8000 ?~g. Discard flow-

through and reuse the collection tube. Repeat this wash step once.

6.7 Place the RNeasy spin column into a new 2-ml collection tube and centrifuge at 8000 ?~g for 2 minutes to dry the membrane.

6.8 Transfer the RNeasy column into a new 1.5-ml collection tube (supplied),and pipette 50 ul of nuclease-free water directly onto the RNeasy membrane without touching the membrane.

6.9 Incubate at ambient temperature for 10 minutes.Elute the cRNA by centrifugation at 8000 ?~g for 1 minute. Do not remove the column.

6.10 Pipette another 50 ul of nuclease-free water directly onto the same RNeasy membrane.

6.11 Incubate at ambient temperature for 10 minutes. Elute the cRNA (into the same tube used in step 6.8)by centrifugation at 8000 ?~g for 1 minute.

6.12 Remove the column. Mix the solution by tapping the side of the tube.

6.13 Move the tube directly to section 7 or store the cRNA at -70 oC. Divide samples into 10 .20 ug aliquots to minimize the number of freeze-thaw cycles.
" CodeLink target preparation labeling P-MEXP-14987 "For details see CodeLink Gene Expression System: Single-Assay Bioarray Hybridization and Detection

Protocol for hybridization and detection

1

Fragmentation of cRNA

1.1 For each bioarray to be loaded, bring 10 ug of cRNA (from step 6.13 of CodeLink target preparation protocol) to a final volume of 20 ul with nuclease-free water in a

thin-walled microcentrifuge tube.

1.2 Add 5 ul of 5fragmentation buffer for each bioarray. Place tube in a thermal cycler and heat for 20 minutes at 94 ?C using the heated lid feature.

1.3 Cool to 0 ?C in the thermal cycler for at least 5 minutes.

2

Preparation of hybridization reaction mixtures

2.1 Set the temperature of the shaker-incubator to 37 ?C for hybridization. Assemble bioarray tray posts from the CodeLink Shaker Kit onto the incubator platform.

2.2 Transfer the cRNA sample from the thin-walled tube to a 1.5-ml microcentrifuge

tube. For each bioarray to be processed, prepare 260 ul of hybridization solution

containing 10 ug of fragmented target cRNA in a 1.5-ml microcentrifuge tube:

78 ul hybridization buffer component A

130 ul hybridization buffer component B

27 ul nuclease-free water

25 ul fragmented cRNA (from Step 1)

260 ul total volume

2.3 Vortex the solution for 5 seconds at maximum speed. Incubate the hybridization

solution at 90 ?C for 5 minutes to denature the cRNA.

2.4 Cool the tube(s) on ice for at least 5 and no more than 30 minutes Load all

bioarrays within 30 minutes of denaturing the cRNA.

3

Loading of reaction mixtures into bioarray chambers

3.1 Set the 12-slide shaker tray on a level surface. Place the bioarrays into the shaker tray with the input/output ports facing up. Load bioarrays in sets of 12 or less.

3.2 Vortex the hybridization reaction mixture for 5 seconds at maximum speed. Centrifuge briefly to gather the liquid at the bottom of the tube. Place the tube back on ice.

3.3 For each bioarray chamber, draw 250 ul into a 1-ml wide-bore pipette tip. Place the 1-ml pipette tip containing the hybridization solution over the array input port closest to the right edge of the slide label and press until the tip forms a seal with the chamber (see Appendix 5 for details).

3.4 Slowly inject the entire sample into the Flex Chamber without using the blowout feature of the pipettor. When the Flex Chamber is full, maintain thumb pressure on the pipettor, hold down the bioarray over the tab region with index finger of opposite hand, and remove the pipette tip from the input port. Discard any excess target mix remaining in the pipette tip. Aspirate any excess fluid surrounding the outside of the port with a pipette tip and discard. Use a lint-free wipe to blot residual fluid from around the port, taking care not to actually touch the port.

3.5 After loading up to 12 bioarrays, seal the Flex Chamber ports using the sealing

strips and port sealing tool as described in Appendix 5. Do not touch the Flex Chamber

or directly depress the port.

4

Hybridization

4.1 Align the 12-slide shaker tray notches with the front and back posts fixed to the shaker-incubator platform to place the loaded shaker tray into the shaker-incubator. The Flex Chamber should be facing up.

4.2 Set the shaker speed to 300 rpm and incubate slides for 18-24 h at 37 ?C. It is

critical that arrays used in any form of comparison are hybridized for the same amount

of time within the given range.

4.3 To prepare for the next step, fill a large reagent reservoir with 240 ml of filtered 0.75TNT buffer. Cover the reservoir and incubate in a 46 ?C water bath overnight.

Post-hybridization wash

5.1 Fill each slot in the medium reagent reservoir with 13 ml of filtered 0.75TNT.

Place the bioarray rack into the reservoir. Leave at ambient temperature.

5.2 Remove bioarrays from the incubator one by one and keep the remaining bioarrays at 37?C until ready for processing. This will ensure that the slides are still warm and aid with the ease of peel.

5.3 Place the bioarray to be processed into the Flex Chamber removal tool.

5.4 Remove the Flex Chamber by lifting the tab and slowly peeling the chamber from the bioarray at a 60? angle.

Chamber Removal Hints: The peel angle prevents creasing of the Flex Chamber.

Carefully observe the slide surface while peeling. If, as you peel, adhesive is separating from the Flex Chamber and sticking to the bioarray surface, then slow down the rate of peeling. A slow peel of approximately 3?5 s is critical to ensure that no adhesive remains on the bioarray after the chamber is removed. It should not take more than 5 minutes to process 12 slides during this step. If adhesive is visible on one edge of the bioarray, place that edge down in the bioarray rack slot (step 5.5).

5.5 Place the bioarray into a slot of the bioarray rack prepared in step 5.1. Use the bioarray position tool, tooth-side down, to ensure the bioarrays are properly seated.

5.6 To avoid potential cross-contamination, rinse the surface of the Flex Chamber removal tool with approximately 5 ml of ambient temperature 0.75TNT buffer dispensed from a squirt bottle. Keep the medium reagent reservoir at ambient temperature until all bioarrays have been processed.

5.7 Repeat steps 5.3-5.6 for each hybridized bioarray.

5.8 Transfer the bioarray rack with bioarrays from the medium reagent reservoir into the pre-warmed, 0.75TNT-filled large reagent reservoir from step 4.3. Replace the lid on the large reagent reservoir and then on the water bath. Incubate at 46 ?C for exactly 1 h; longer incubation time may significantly reduce signal intensities.

6

Detection with streptavidin-dye conjugate

6.1 Fill each slot in the small reagent reservoir with 3.4 ml of Cy5-Streptavidin working solution (Appendix 1). Leave at ambient temperature. Cover the small reagent reservoir with a black lid to prevent photobleaching of the fluorophore by ambient light.

6.2 Remove the bioarray rack with bioarrays from the large reagent reservoir at 46 ?C, and place into the small reagent reservoir containing the Cy5-Streptavidin working solution. Cover with the lid and incubate bioarrays at ambient temperature for 30 minutes.

6.3 During incubation, prepare for the wash steps by filling three large reagent reservoirs each with 240 ml of ambient temperature 1TNT buffer.

6.4 After the 30 minutes incubation, remove the bioarray rack with bioarrays from the staining solution and place into one large reagent reservoir containing 1TNT buffer (prepared in 6.3). Do not drain the solution from the bioarrays. Following an initial gentle up-and-down agitation, incubate the bioarrays at ambient temperature for 5 minutes covered from light.

6.5 Remove the bioarray rack from the first large reagent reservoir with 1TNT buffer

and place into a second large reagent reservoir containing 1TNT buffer. Again, do

not attempt to drain the solution from the bioarrays and gently agitate the bioarray rack.

Incubate at ambient temperature for 5 minutes, covered from light. Repeat this step

with two additional large reagent reservoirs containing fresh 1TNT buffer for a third

and fourth wash.

6.6 During the third wash, thoroughly rinse a large reagent reservoir with distilled water

and dry it. Completely fill this reservoir with the final rinse 0.1SSC/ 0.05% Tween 20

solution (Appendix 1).

6.7 Transfer the bioarray rack into the large reagent reservoir completely filled with 0.1

SSC/ 0.05% Tween 20 at ambient temperature. Incubate the slides for 30 seconds

while continually agitating mildly up and down.

6.8 Remove the bioarray rack from the large reagent reservoir and blot the bottom edge of the bioarrays briefly on an absorbent paper towel. Place the bioarray rack in a clean, dry medium reagent reservoir. Dry the bioarrays by centrifugation in the Qiagen Sigma 4-15C centrifuge with corresponding bucket rotor (2 ?96-well plate) or similar system using following settings:

speed: 2000 rpm (644 ?g)

acceleration: 9

deceleration: 9

time: 3 minutes

6.9 To easily remove the bioarrays from the bioarray rack, place the bioarray rack with slides into the bioarray removal tool. Place the dry bioarrays into a light-protected slide box until they are scanned. Bioarrays should be scanned within two days of assay completion.

Note: On high density products (such as Whole Genome bioarrays), an outline of the removed Flex chamber will be visible on the bioarray surface; whereas the 10K and 20K products will not show this outline. This will not affect the bioarray performance.

6.10 Repeatedly rinse all reservoirs with deionized water to clean, and invert to dry.

6.11 Wash the rack with Alconox soap, scrubbing between the rails with a pipe cleaner style brush. Rinse thoroughly with deionized water to remove residual soap. Air-dry the rack.

" CodeLink Gene Expression Hybridisation hybridization P-MEXP-14988 "GenePix scanner, 5 micron resolution, 600PMT, 100%Power" CodeLink Scanning image_acquisition Hybridization section index BioSource BioSourceMaterial BioMaterialCharacteristics[Organism] BioMaterialCharacteristics[BioSourceProvider] BioMaterialCharacteristics[DevelopmentalStage] BioMaterialCharacteristics[Age] BioMaterialCharacteristics[TimeUnit] BioMaterialCharacteristics[OrganismPart] BioMaterialCharacteristics[Sex] BioMaterialCharacteristics[Individual] BioMaterialCharacteristics[DiseaseState] FactorValue[DiseaseState] BioMaterialCharacteristics[CellType] BioMaterialCharacteristics[ClinicalHistory] FactorValue[CellType] Protocol[grow] Protocol[extraction] Protocol[pool] Extract LabeledExtract Protocol[labeling] Dye Hybridization Scan File[raw] File[normalized] File[exp] Array[accession] Protocol[hybridization] Protocol[scanning] 23 SAMPLE_human_822 organism_part Homo sapiens "Royal Free Hospital, London,UK" adult mammary gland female Human_822 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_agil1 L_pool_cy3_agil1 251239114659.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 4 SAMPLE_human_621 organism_part Homo sapiens "Middlesex University Hospital, London,UK" adult 38 years mammary gland female Human_621 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_agil1 M_pool_cy3_agil1 251239114660.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 42 SAMPLE_human_695 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_695 invasive lobular carcinoma invasive lobular carcinoma breast epithelial "grad1,size42, 9/15 lymph node, ESR1 positive, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_agil1 T_pool_cy3_agil1 251239114661.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 26 SAMPLE_human_1040 organism_part Homo sapiens "Middlesex Hospital, London,UK" adult 33 years mammary gland female Human_1040 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_agil1 L_pool_cy5_agil1 251239119797.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 7 SAMPLE_human_723 organism_part Homo sapiens "St. George's University Hospital, London,UK" adult 32 years mammary gland female Human_723 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_agil1 M_pool_cy5_agil1 251239119798.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 45 SAMPLE_human_845 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_845 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size50,vascular invasion, 2/9 lymph node,ESR1 positive, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_agil1 T_pool_cy5_agil1 251239119800.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 27 SAMPLE_human_1053 organism_part Homo sapiens "Ashstead Hospital, London,UK" adult 22 years mammary gland female Human_1053 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_agil2 L_pool_cy5_agil2 251239125237.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 8 SAMPLE_human_729 organism_part Homo sapiens "St. George's Hospital, London,UK" adult 31 years mammary gland female Human_729 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_agil2 M_pool_cy5_agil2 251239125238.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 46 SAMPLE_human_896 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_896 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "size45, 0/2 lymph node" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_agil2 T_pool_cy5_agil2 251239125239.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 9 SAMPLE_human_1098 organism_part Homo sapiens "Queen Victoria Hospital, London,UK" adult 26 years mammary gland female Human_1098 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_agil3 M_pool_cy5_agil3 251239125240.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 47 SAMPLE_human_983 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_983 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size15,vascular invasion, ESR1 negative, HER2 positive, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_agil3 T_pool_cy5_agil3 251239125243.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 24 SAMPLE_human_1016 organism_part Homo sapiens "St. Anthony's Hospital, London,UK" adult 30 years mammary gland female Human_1016 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_agil2 L_pool_cy3_agil2 251239125464.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 5 SAMPLE_human_688 organism_part Homo sapiens "St. George's Hospital, London,UK" adult 26 years mammary gland female Human_688 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_agil2 M_pool_cy3_agil2 251239125465.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 28 SAMPLE_human_1123 organism_part Homo sapiens "University College London Hospital, London,UK" adult 32 years mammary gland female Human_1123 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_agil3 L_pool_cy5_agil3 251239125466.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 43 SAMPLE_human_725 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_725 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size35,vascular invasion, 1/15 lymph node, ESR1 positive" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_agil2 T_pool_cy3_agil2 251239125467.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 25 SAMPLE_human_1031 organism_part Homo sapiens "St. Elisabeth Hospital, London,UK" adult 33 years mammary gland female Human_1031 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_agil3 L_pool_cy3_agil3 251239125951.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 6 SAMPLE_human_697 organism_part Homo sapiens "St. George's University Hospital, London,UK" adult 29 years mammary gland female Human_697 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_agil3 M_pool_cy3_agil3 251239125953.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 44 SAMPLE_human_842 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_842 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,vascular invasion, 1/10 lymph node, ESR1 positive, progesteron receptor positive" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_agil3 T_pool_cy3_agil3 251239125954.gpr A-MEXP-218 P-MEXP-6162 P-MEXP-10145 32 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_breakthrough1 L_pool_cy5_breakthrough1 90000310.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 13 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_breakthrough1 M_pool_cy5_breakthrough1 90000311.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 51 SAMPLE_human_1052 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1052 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size35, ESR1 negative, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_breakthrough1 T_pool_cy5_breakthrough1 90000312.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 29 SAMPLE_human_1130 organism_part Homo sapiens "University College London Hospital, London,UK" adult 32 years mammary gland female Human_1130 normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_breakthrough1 L_pool_cy3_breakthrough1 90000337.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 10 SAMPLE_human_794 organism_part Homo sapiens "Ashstead Hospital, London,UK" adult 39 years mammary gland female Human_794 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_breakthrough1 M_pool_cy3_breakthrough1 90000338.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 48 SAMPLE_human_1000 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1000 invasive ductual carcinoma invasive ductual carcinoma breast epithelial breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_breakthrough1 T_pool_cy3_breakthrough1 90000339.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 33 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_breakthrough2 L_pool_cy5_breakthrough2 90000340.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 14 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_breakthrough2 M_pool_cy5_breakthrough2 90000341.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 52 SAMPLE_human_1062 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1062 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad2,size20,vascular invasion, 1/25 lymph node, ESR1 positive, HER2 negative, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_breakthrough2 T_pool_cy5_breakthrough2 90000342.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 30 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_breakthrough2 L_pool_cy3_breakthrough2 90000343.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 11 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_breakthrough2 M_pool_cy3_breakthrough2 90000344.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 49 SAMPLE_human_1033 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1033 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size58, 1/15 lymph node, ESR1 negative, HER2 negative, progesteron receptor negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_breakthrough2 T_pool_cy3_breakthrough2 90000345.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 34 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 L_pool_cy5_breakthrough3 L_pool_cy5_breakthrough3 90000418.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 15 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 M_pool_cy5_breakthrough3 M_pool_cy5_breakthrough3 90000419.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 53 SAMPLE_human_1063 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1063 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size45,vascular invasion, ESR1 positive, HER2 positive, progesteron receptor positive" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 T_pool_cy5_breakthrough3 T_pool_cy5_breakthrough3 90000420.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 31 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 L_pool_cy3_breakthrough3 L_pool_cy3_breakthrough3 90000421.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 12 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 M_pool_cy3_breakthrough3 M_pool_cy3_breakthrough3 90000422.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 50 SAMPLE_human_1045 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_1045 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad2,size50, ESR1 negative, HER2 negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 T_pool_cy3_breakthrough3 T_pool_cy3_breakthrough3 90000423.gpr A-MEXP-259 P-MEXP-10140 P-MEXP-10145 106 normal luminal E_luminal_pool 2nd_L_pool_L_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy3_breakthrough1 2nd_L_pool_cy3_breakthrough1 95000061.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 138 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy3_breakthrough1 2nd_L_pool_cy3_breakthrough1 95000061.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 107 normal luminal E_luminal_pool 2nd_L_pool_L_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy3_breakthrough2 2nd_L_pool_cy3_breakthrough2 95000062.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 139 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy3_breakthrough2 2nd_L_pool_cy3_breakthrough2 95000062.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 94 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy3_breakthrough1 2nd_M_pool_cy3_breakthrough1 95000063.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 130 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy3_breakthrough1 2nd_M_pool_cy3_breakthrough1 95000063.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 95 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy3_breakthrough2 2nd_M_pool_cy3_breakthrough2 95000064.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 131 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy3_breakthrough2 2nd_M_pool_cy3_breakthrough2 95000064.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 118 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy3_breakthrough95000065 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy3_breakthrough95000065 2nd_T_pool_cy3_breakthrough95000065 95000065.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 146 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough95000065 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy3_breakthrough95000065 2nd_T_pool_cy3_breakthrough95000065 95000065.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 119 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy3_breakthrough95000066 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy3_breakthrough95000066 2nd_T_pool_cy3_breakthrough95000066 95000066.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 147 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough95000066 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy3_breakthrough95000066 2nd_T_pool_cy3_breakthrough95000066 95000066.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 110 normal luminal E_luminal_pool 2nd_L_pool_L_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy5_breakthrough1 2nd_L_pool_cy5_breakthrough1 95000067.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 142 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy5_breakthrough1 2nd_L_pool_cy5_breakthrough1 95000067.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 111 normal luminal E_luminal_pool 2nd_L_pool_L_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy5_breakthrough2 2nd_L_pool_cy5_breakthrough2 95000068.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 143 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy5_breakthrough2 2nd_L_pool_cy5_breakthrough2 95000068.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 98 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy5_breakthrough1 2nd_M_pool_cy5_breakthrough1 95000069.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 134 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy5_breakthrough1 2nd_M_pool_cy5_breakthrough1 95000069.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 99 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy5_breakthrough2 2nd_M_pool_cy5_breakthrough2 95000070.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 135 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy5_breakthrough2 2nd_M_pool_cy5_breakthrough2 95000070.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 122 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy5_breakthrough1 2nd_T_pool_cy5_breakthrough1 95000071.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 150 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy5_breakthrough1 2nd_T_pool_cy5_breakthrough1 95000071.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 123 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy5_breakthrough2 2nd_T_pool_cy5_breakthrough2 95000072.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 151 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy5_breakthrough2 2nd_T_pool_cy5_breakthrough2 95000072.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 112 normal luminal E_luminal_pool 2nd_L_pool_L_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy5_breakthrough3 2nd_L_pool_cy5_breakthrough3 95000073.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 144 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy5_breakthrough3 2nd_L_pool_cy5_breakthrough3 95000073.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 113 normal luminal E_luminal_pool 2nd_L_pool_L_cy5_breakthrough4 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy5_breakthrough4 2nd_L_pool_cy5_breakthrough4 95000074.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 145 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough4 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy5_breakthrough4 2nd_L_pool_cy5_breakthrough4 95000074.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 100 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy5_breakthrough3 2nd_M_pool_cy5_breakthrough3 95000075.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 136 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy5_breakthrough3 2nd_M_pool_cy5_breakthrough3 95000075.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 101 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy5_breakthrough4 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy5_breakthrough4 2nd_M_pool_cy5_breakthrough4 95000076.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 137 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough4 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy5_breakthrough4 2nd_M_pool_cy5_breakthrough4 95000076.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 124 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy5_breakthrough3 2nd_T_pool_cy5_breakthrough3 95000077.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 152 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy5_breakthrough3 2nd_T_pool_cy5_breakthrough3 95000077.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 125 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy5_breakthrough4 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy5_breakthrough4 2nd_T_pool_cy5_breakthrough4 95000078.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 153 REF sources E_REF 2nd_REF_pool_L_cy3_breakthrough4 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy5_breakthrough4 2nd_T_pool_cy5_breakthrough4 95000078.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 108 normal luminal E_luminal_pool 2nd_L_pool_L_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy3_breakthrough3 2nd_L_pool_cy3_breakthrough3 95000079.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 140 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy3_breakthrough3 2nd_L_pool_cy3_breakthrough3 95000079.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 109 normal luminal E_luminal_pool 2nd_L_pool_L_cy3_breakthrough4 P-TABM-AnitaG-10115 Cy3 2nd_L_pool_cy3_breakthrough4 2nd_L_pool_cy3_breakthrough4 95000080.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 141 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough4 P-TABM-AnitaG-10115 Cy5 2nd_L_pool_cy3_breakthrough4 2nd_L_pool_cy3_breakthrough4 95000080.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 96 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy3_breakthrough3 2nd_M_pool_cy3_breakthrough3 95000081.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 132 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy3_breakthrough3 2nd_M_pool_cy3_breakthrough3 95000081.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 97 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_L_cy3_breakthrough4 P-TABM-AnitaG-10115 Cy3 2nd_M_pool_cy3_breakthrough4 2nd_M_pool_cy3_breakthrough4 95000082.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 133 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough4 P-TABM-AnitaG-10115 Cy5 2nd_M_pool_cy3_breakthrough4 2nd_M_pool_cy3_breakthrough4 95000082.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 120 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy3_breakthrough95000083 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy3_breakthrough95000083 2nd_T_pool_cy3_breakthrough95000083 95000083.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 148 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough95000083 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy3_breakthrough95000083 2nd_T_pool_cy3_breakthrough95000083 95000083.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 121 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_L_cy3_breakthrough95000084 P-TABM-AnitaG-10115 Cy3 2nd_T_pool_cy3_breakthrough95000084 2nd_T_pool_cy3_breakthrough95000084 95000084.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 149 REF sources E_REF 2nd_REF_pool_L_cy5_breakthrough95000084 P-TABM-AnitaG-10115 Cy5 2nd_T_pool_cy3_breakthrough95000084 2nd_T_pool_cy3_breakthrough95000084 95000084.gpr A-MEXP-339 P-MEXP-10140 P-MEXP-10145 20 SAMPLE_human_723L organism_part Homo sapiens "St. George's Hospital, London,UK" adult 32 years mammary gland female Human_723L normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_affy1 P-AFFY-2 biotin L_pool_affy1 L_pool_affy1 L1.CEL L1.EXP A-AFFY-44 21 SAMPLE_human_729L organism_part Homo sapiens "St. George's Hospital, London,UK" adult 31 years mammary gland female Human_729L normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_affy2 P-AFFY-2 biotin L_pool_affy2 L_pool_affy2 L2.CEL L2.EXP A-AFFY-44 22 SAMPLE_human_697L organism_part Homo sapiens "St. George's Hospital, London,UK" adult 29 years mammary gland female Human_697L normal normal luminal epithelial Reduction mammoplasties luminal epithelial P-MEXP-975 P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_affy3 P-AFFY-2 biotin L_pool_affy3 L_pool_affy3 L3.CEL L3.EXP A-AFFY-44 1 SAMPLE_human_352 organism_part Homo sapiens "Queen Mary's University Hospital, London,UK" adult 30 years mammary gland female Human_352 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_affy1 P-AFFY-2 biotin M_pool_affy1 M_pool_affy1 M1.CEL M1.EXP A-AFFY-44 2 SAMPLE_human_453 organism_part Homo sapiens "Queen Mary's University Hospital, London,UK" adult 22 years mammary gland female Human_453 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_affy2 P-AFFY-2 biotin M_pool_affy2 M_pool_affy2 M2.CEL M2.EXP A-AFFY-44 3 SAMPLE_human_463 organism_part Homo sapiens "Queen Mary's University Hospital, London,UK" adult 31 years mammary gland female Human_463 normal normal myoepithelial Reduction mammoplasties myoepithelial P-MEXP-976 P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_affy3 P-AFFY-2 biotin M_pool_affy3 M_pool_affy3 M3.CEL M3.EXP A-AFFY-44 39 SAMPLE_human_489 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_489 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size25,vascular invasion, ESR1 positive, HER2 negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_affy1 P-AFFY-2 biotin T_pool_affy1 T_pool_affy1 T1.CEL T1.EXP A-AFFY-44 40 SAMPLE_human_552 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_552 invasive ductual carcinoma invasive ductual carcinoma breast epithelial "grad3,size40,vascular invasion, 8/9 lymph node, ESR1 negative, HER2 negative" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_affy2 P-AFFY-2 biotin T_pool_affy2 T_pool_affy2 T2.CEL T2.EXP A-AFFY-44 41 SAMPLE_human_593 organism_part Homo sapiens "University College London Hospital, London,UK" adult mammary gland female Human_593 invasive lobular carcinoma invasive lobular carcinoma breast epithelial "grad2,size35, 1/9 lymph node, ESR1 positive" breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_affy3 P-AFFY-2 biotin T_pool_affy3 T_pool_affy3 T3.CEL T3.EXP A-AFFY-44 116 normal luminal E_luminal_pool 2nd_L_pool_amersham3 P-MEXP-14985 Cy5 2nd_L_pool_amersham3 2nd_L_pool_amersham3 T00250228.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 117 normal luminal E_luminal_pool 2nd_L_pool_amersham4 P-MEXP-14985 Cy5 2nd_L_pool_amersham4 2nd_L_pool_amersham4 T00250229.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 104 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_amersham3 P-MEXP-14985 Cy5 2nd_M_pool_amersham3 2nd_M_pool_amersham3 T00250230.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 105 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_amersham4 P-MEXP-14985 Cy5 2nd_M_pool_amersham4 2nd_M_pool_amersham4 T00250231.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 128 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_amersham3 P-MEXP-14985 Cy5 2nd_T_pool_amersham3 2nd_T_pool_amersham3 T00250232.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 129 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_amersham4 P-MEXP-14985 Cy5 2nd_T_pool_amersham4 2nd_T_pool_amersham4 T00250233.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 114 normal luminal E_luminal_pool 2nd_L_pool_amersham1 P-MEXP-14985 Cy5 2nd_L_pool_amersham1 2nd_L_pool_amersham1 T00253433.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 115 normal luminal E_luminal_pool 2nd_L_pool_amersham2 P-MEXP-14985 Cy5 2nd_L_pool_amersham2 2nd_L_pool_amersham2 T00253434.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 102 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_amersham1 P-MEXP-14985 Cy5 2nd_M_pool_amersham1 2nd_M_pool_amersham1 T00253435.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 103 normal myoepithelial E_myoepithelial_pool 2nd_M_pool_amersham2 P-MEXP-14985 Cy5 2nd_M_pool_amersham2 2nd_M_pool_amersham2 T00253436.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 126 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_amersham1 P-MEXP-14985 Cy5 2nd_T_pool_amersham1 2nd_T_pool_amersham1 T00253437.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 127 invasive ductual carcinoma breast epithelial E_tumour_pool 2nd_T_pool_amersham2 P-MEXP-14985 Cy5 2nd_T_pool_amersham2 2nd_T_pool_amersham2 T00253438.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 35 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_amersham1 P-MEXP-14985 Cy5 L_pool_amersham1 L_pool_amersham1 T00297797.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 36 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_amersham2 P-MEXP-14985 Cy5 L_pool_amersham2 L_pool_amersham2 T00297799.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 37 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_amersham3 P-MEXP-14985 Cy5 L_pool_amersham3 L_pool_amersham3 T00297800.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 38 normal luminal epithelial P-MEXP-972 P-MEXP-10844 E_luminal_pool L_pool_amersham4 P-MEXP-14985 Cy5 L_pool_amersham4 L_pool_amersham4 T00297801.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 16 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_amersham1 P-MEXP-14985 Cy5 M_pool_amersham1 M_pool_amersham1 T00297802.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 17 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_amersham2 P-MEXP-14985 Cy5 M_pool_amersham2 M_pool_amersham2 T00297803.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 18 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_amersham3 P-MEXP-14985 Cy5 M_pool_amersham3 M_pool_amersham3 T00297804.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 19 normal myoepithelial P-MEXP-972 P-MEXP-10843 E_myoepithelial_pool M_pool_amersham4 P-MEXP-14985 Cy5 M_pool_amersham4 M_pool_amersham4 T00297805.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 54 invasive ductual carcinoma breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_amersham1 P-MEXP-14985 Cy5 T_pool_amersham1 T_pool_amersham1 T00297808.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 55 invasive ductual carcinoma breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_amersham2 P-MEXP-14985 Cy5 T_pool_amersham2 T_pool_amersham2 T00297810.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 56 invasive ductual carcinoma breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_amersham3 P-MEXP-14985 Cy5 T_pool_amersham3 T_pool_amersham3 T00297811.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 57 invasive ductual carcinoma breast epithelial P-MEXP-972 P-MEXP-10845 E_tumour_pool T_pool_amersham4 P-MEXP-14985 Cy5 T_pool_amersham4 T_pool_amersham4 T00297812.txt A-GEHB-1 P-MEXP-14987 P-MEXP-14988 58 REF sources E_REF REF_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_agil1 M_pool_cy3_agil1 59 REF sources E_REF REF_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_agil2 M_pool_cy3_agil2 60 REF sources E_REF REF_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_agil3 M_pool_cy3_agil3 61 REF sources E_REF REF_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_agil1 M_pool_cy5_agil1 62 REF sources E_REF REF_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_agil2 M_pool_cy5_agil2 63 REF sources E_REF REF_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_agil3 M_pool_cy5_agil3 64 REF sources E_REF REF_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_breakthrough1 M_pool_cy3_breakthrough1 65 REF sources E_REF REF_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_breakthrough2 M_pool_cy3_breakthrough2 66 REF sources E_REF REF_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 M_pool_cy3_breakthrough3 M_pool_cy3_breakthrough3 67 REF sources E_REF REF_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_breakthrough1 M_pool_cy5_breakthrough1 68 REF sources E_REF REF_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_breakthrough2 M_pool_cy5_breakthrough2 69 REF sources E_REF REF_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 M_pool_cy5_breakthrough3 M_pool_cy5_breakthrough3 70 REF sources E_REF REF_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_agil1 L_pool_cy3_agil1 71 REF sources E_REF REF_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_agil2 L_pool_cy3_agil2 72 REF sources E_REF REF_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_agil3 L_pool_cy3_agil3 73 REF sources E_REF REF_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_agil1 L_pool_cy5_agil1 74 REF sources E_REF REF_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_agil2 L_pool_cy5_agil2 75 REF sources E_REF REF_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_agil3 L_pool_cy5_agil3 76 REF sources E_REF REF_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_breakthrough1 L_pool_cy3_breakthrough1 77 REF sources E_REF REF_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_breakthrough2 L_pool_cy3_breakthrough2 78 REF sources E_REF REF_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 L_pool_cy3_breakthrough3 L_pool_cy3_breakthrough3 79 REF sources E_REF REF_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_breakthrough1 L_pool_cy5_breakthrough1 80 REF sources E_REF REF_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_breakthrough2 L_pool_cy5_breakthrough2 81 REF sources E_REF REF_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 L_pool_cy5_breakthrough3 L_pool_cy5_breakthrough3 82 REF sources E_REF REF_pool_cy5_agil1 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_agil1 T_pool_cy3_agil1 83 REF sources E_REF REF_pool_cy5_agil2 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_agil2 T_pool_cy3_agil2 84 REF sources E_REF REF_pool_cy5_agil3 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_agil3 T_pool_cy3_agil3 85 REF sources E_REF REF_pool_cy3_agil1 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_agil1 T_pool_cy5_agil1 86 REF sources E_REF REF_pool_cy3_agil2 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_agil2 T_pool_cy5_agil2 87 REF sources E_REF REF_pool_cy3_agil3 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_agil3 T_pool_cy5_agil3 88 REF sources E_REF REF_pool_cy5_breakthrough1 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_breakthrough1 T_pool_cy3_breakthrough1 89 REF sources E_REF REF_pool_cy5_breakthrough2 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_breakthrough2 T_pool_cy3_breakthrough2 90 REF sources E_REF REF_pool_cy5_breakthrough3 P-TABM-AnitaG-10115 Cy5 T_pool_cy3_breakthrough3 T_pool_cy3_breakthrough3 91 REF sources E_REF REF_pool_cy3_breakthrough1 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_breakthrough1 T_pool_cy5_breakthrough1 92 REF sources E_REF REF_pool_cy3_breakthrough2 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_breakthrough2 T_pool_cy5_breakthrough2 93 REF sources E_REF REF_pool_cy3_breakthrough3 P-TABM-AnitaG-10115 Cy3 T_pool_cy5_breakthrough3 T_pool_cy5_breakthrough3